ApoM-S1P Modulates Ox-LDL-Induced Inflammation Through the PI3K/Akt Signaling Pathway in HUVECs
- 144 Downloads
Studies have shown that apolipoprotein M (apoM), the main carrier of sphingosine-1-phosphate (S1P), is closely related to lipid metabolism and inflammation. While there are many studies on apoM and lipid metabolism, little is known about the role of apoM in inflammation. Atherosclerosis is a chronic inflammatory process. To clarify what role apoM plays in atherosclerosis, we used oxidized low-density lipoprotein (ox-LDL) to induce an inflammatory model of atherosclerosis. Our preliminary results indicate that ox-LDL upregulates the expression of S1P receptor 2 (S1PR2) in human umbilical vein endothelial cells (HUVECs). Ox-LDL-induced HUVECs were treated with apoM-bound S1P (apoM-S1P), free S1P or apoM, and apoM-S1P was found to significantly inhibit the expression of inflammatory factors and adhesion molecules. In addition, apoM-S1P inhibits ox-LDL-induced cellular inflammation via S1PR2. Moreover, apoM-S1P induces phosphorylation of phosphatidylinositol 3-kinase (PI3K)/Akt, preventing nuclear translocation of nuclear factor-κB (NF-κB). PI3K-specific inhibitors and Akt inhibitors suppress apoM-S1P/S1PR2-induced interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) release and affect nuclear translocation of NF-κB. In conclusion, the results demonstrate for the first time that apoM-S1P inhibits ox-LDL-induced inflammation in HUVECs via the S1PR2-mediated PI3K/Akt signaling pathway. This finding may aid in the development of new treatments for atherosclerosis.
KEY WORDSapoM-S1P ox-LDL inflammatory factors adhesion molecules atherosclerosis
The authors sincerely acknowledge the financial assistance provided by the National Natural Science Foundation of China (No. 81770490) and the Construct Program of the Key Discipline in Hunan Province (Basic Medicine Sciences in University of South China).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 5.Ma, X., Y.W. Hu, Z.L. Zhao, L. Zheng, Y.R. Qiu, J.L. Huang, X.J. Wu, X.R. Mao, J. Yang, J.Y. Zhao, S.F. Li, M.N. Gu, and Q. Wang. 2013. Anti-inflammatory effects of propofol are mediated by apolipoprotein M in a hepatocyte nuclear factor-1a-dependent manner. Archives of Biochemistry and Biophysics 533: 1–10.CrossRefGoogle Scholar
- 6.Christoffersen, C., M. Jauhiainen, M. Moser, B. Porse, C. Ehnholm, M. Boesl, B. Dahlbäck, and L.B. Nielsen. 2008. Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J Biol Chem 283: 1839–1847.CrossRefGoogle Scholar
- 7.Sevvana, M., J. Ahnström, C. Egerer-Sieber, H.A. Lange, B. Dahlbäck, and Y.A. Muller. 2009. Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoprotein M. J Biol 393: 920–936.Google Scholar
- 8.Christoffersen, C., H. binata, S.B. Kumaraswamy, S. Galvani, J. Ahnström, M. Sevvana, C. Egerer-Sieber, Y.A. Muller, and T. Hla. 2011. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proceedings of the National Academy of Sciences of the United States of America 108: 9613–9618.CrossRefGoogle Scholar
- 12.Liu, H., H. Jin, X. Yue, J. Han, P. Baum, D.R. Abendschein, and Z. Tu. 2017. PET study of sphingosine-1-phosphate receptor 1 expression in response to vascular inflammation in a rat model of carotid injury. Molecular Imaging 6: 1536012116689770.Google Scholar
- 14.Johnston, T.P. 2009. Poloxamer 407 increases soluble adhesion molecules, ICAM-1, VCAM-1 and E-selectin, in C57BL/6 mice. The Journal of Pharmacy and Pharmacology 61: 1681–1688.Google Scholar
- 15.Pyne, N.J., M. McNaughton, S. Boomkamp, N. MacRitchie, C. Evangelisti, A.M. Martelli, H.R. Jiang, S. Ubhi, and S. Pyne. 2016. Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation. Advances in Biological Regulation 60: 151–159.CrossRefGoogle Scholar
- 17.Hamed, S. 2006. Endothelial progenitor cells and atherosclerosis. Harefuah 145: 358–361.Google Scholar
- 21.Kosmas, C.E., I. Martinez, A. Sourlas, K.V. Bouza, F.N. Campos, V. Torres, P.D. Montan, and E. Guzman. 2018. High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease. Drugs Context 7: 212525.Google Scholar
- 27.Jiang, Y., L.L. Jiang, X.M. Maimaitirexiati, Y. Zhang, and L. Wu. 2015. Irbesartan attenuates TNF-α-induced ICAM-1, VCAM-1, and E-selectin expression through suppression of NF-κB pathway in HUVECs. European Review for Medical and Pharmacological Sciences 19: 3295–3302.Google Scholar